Retention among transgender women treated with dolutegravir associated with tenofovir/ lamivudine or emtricitabine in Argentina: TransViiV study

Simple item page
dc.contributor.authorFrola, Claudia
dc.contributor.authorAristegui, Ines
dc.contributor.authorFigueroa, María I.
dc.contributor.authorRadusky, Pablo
dc.contributor.authorCardozo, Nadir
dc.contributor.authorZalazar, Virginia
dc.contributor.authorCesar, Carina
dc.contributor.authorPatterson, Patricia
dc.contributor.authorFink, Valeria
dc.contributor.authorGun, Ana
dc.contributor.authorCahn, Pedro
dc.contributor.authorSued, Omar
dc.date.accessioned2024-05-20T18:24:33Z
dc.date.available2024-05-20T18:24:33Z
dc.date.issued2023-01
dc.description.abstractIn Argentina, transgender women (TGW) have a high HIV prevalence (34%). However, this population shows lower levels of adherence, retention in HIV care and viral suppression than cisgender patients. The World Health Organization (WHO) recommends the transition to dolutegravir (DTG)-based regimens to reduce adverse events and improve adherence and retention. The purpose of this study was to determine retention, adherence and viral suppression in naïve TGW starting a DTG-based first-line antiretroviral treatment (ART) and to identify clinical and psychosocial factors associated with retention. We designed a prospective, open-label, single-arm trial among ART-naïve HIV positive TGW (Clinical Trial Number: NCT03033836). Participants were followed at weeks 4, 8, 12, 24, 36 and 48, in a trans-affirmative HIV care service that included peer navigators, between December, 2015 and May, 2019. Retention was defined as the proportion of TGW retained at week 48 and adherence was self-reported. Viral suppression at <50 copies/mL was evaluated using snapshot algorithm and as per protocol analysis. Of 75 TGW screened, 61 were enrolled. At baseline, median age was 28 y/o., HIV-1-RNA (pVL) 46,908 copies/mL and CD4+ T-cell count 383 cells/mm3. At week 48, 77% were retained and 72% had viral suppression (97% per protocol). The regimen was well tolerated and participants reported high adherence (about 95%). Eleven of the fourteen TGW who discontinued or were lost to follow-up had undetectable pVL at their last visit. Older age was associated with better retention. DTG-based treatment delivered by a trans-competent team in a trans-affirmative service was safe and well tolerated by TGW and associated with high retention, high adherence and high viral suppression at 48 weeks among those being retained.
dc.identifier.citationFrola CE, Aristegui I, Figueroa MI, Radusky PD, Cardozo N, Zalazar V, et al. (2023) Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study. PLoS ONE 18(1): e0279996. https://doi.org/ 10.1371/journal.pone.0279996
dc.identifier.otherhttps://doi.org/ 10.1371/journal.pone.0279996
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/972
dc.language.isoen
dc.publisherPlos
dc.relation.ispartofseriesPLoS ONE ; 18(1)
dc.titleRetention among transgender women treated with dolutegravir associated with tenofovir/ lamivudine or emtricitabine in Argentina: TransViiV study
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12_2023_Frola_Retention in care among transgender women treated with Dolutegravir associated with TenofovirLamivudine or Emtricitabine in Argentina TransViiV study.pdf
Size:
862.76 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Articulos científicos